Literature DB >> 24486593

Downregulation of FOXO3a promotes tumor metastasis and is associated with metastasis-free survival of patients with clear cell renal cell carcinoma.

Dong Ni1, Xin Ma, Hong-Zhao Li, Yu Gao, Xin-Tao Li, Yu Zhang, Qing Ai, Peng Zhang, Er-Lin Song, Qing-Bo Huang, Yang Fan, Xu Zhang.   

Abstract

PURPOSE: To explore the mechanisms underlying clear-cell renal cell carcinoma (ccRCC) metastasis using transcriptional profiling and bioinformatics analysis of ccRCC samples, and to elucidate the role of FOXO3a in ccRCC metastasis. EXPERIMENTAL
DESIGN: Gene expression profiling was performed using four primary metastatic and five primary nonmetastatic ccRCC samples. The mRNA and protein levels of FOXO3a in ccRCC samples were investigated by real-time reverse transcription PCR and immunohistochemistry, respectively. The association between metastasis-free survival of patients with ccRCC and FOXO3a mRNA levels was analyzed. Biologic functions of FOXO3a in renal cancer cell lines were investigated. The influence of FOXO3a on tumor metastasis was also studied in vivo orthotopic xenograft tumor model. Finally, the mechanism by which FOXO3a attenuation could increase invasion and migration of tumor cells was explored.
RESULTS: Bioinformatics analysis of the profiling data identified FOXO3a as a key factor in ccRCC metastasis. FOXO3a expression was decreased in primary metastatic ccRCC samples. Patients with low FOXO3a mRNA levels had poor metastasis-free survival (P = 0.003). Knocking down FOXO3a induced tumor cell invasion and migration in the nonmetastatic ccRCC cells. Induced FOXO3a overexpression in SN12-PM6 cells could inhibit tumor metastasis in vivo. Downregulation of FOXO3a increased SNAIL1 expression, thereby activating the epithelial-mesenchymal transition (EMT) of RCC cell lines.
CONCLUSIONS: The loss of FOXO3a induced EMT of tumor cells by upregulating SNAIL1, which promoted tumor cells metastasis in vitro and in vivo. Thus, FOXO3a could be considered as an independent prognostic factor in ccRCC metastasis and could be a marker of occult metastases. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24486593     DOI: 10.1158/1078-0432.CCR-13-1687

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  Activation of FOXO3a suggests good prognosis of patients with radically resected gastric cancer.

Authors:  Shan Yu; Yiyi Yu; Yihong Sun; Xuefei Wang; Rongkui Luo; Naiqing Zhao; Wen Zhang; Qian Li; Yuehong Cui; Yan Wang; Wei Li; Tianshu Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 2.  FoxO transcription factors in cancer metabolism.

Authors:  Raj Kumar Yadav; Anoop Singh Chauhan; Li Zhuang; Boyi Gan
Journal:  Semin Cancer Biol       Date:  2018-01-05       Impact factor: 15.707

Review 3.  AKT in cancer: new molecular insights and advances in drug development.

Authors:  Prabhjot S Mundi; Jasgit Sachdev; Carolyn McCourt; Kevin Kalinsky
Journal:  Br J Clin Pharmacol       Date:  2016-06-27       Impact factor: 4.335

4.  CD147 augmented monocarboxylate transporter-1/4 expression through modulation of the Akt-FoxO3-NF-κB pathway promotes cholangiocarcinoma migration and invasion.

Authors:  Paweena Dana; Saowaluk Saisomboon; Ryusho Kariya; Seiji Okada; Sumalee Obchoei; Kanlayanee Sawanyawisuth; Chaisiri Wongkham; Chawalit Pairojkul; Sopit Wongkham; Kulthida Vaeteewoottacharn
Journal:  Cell Oncol (Dordr)       Date:  2019-11-15       Impact factor: 6.730

5.  Bayesian data integration and variable selection for pan-cancer survival prediction using protein expression data.

Authors:  Arnab Kumar Maity; Anirban Bhattacharya; Bani K Mallick; Veerabhadran Baladandayuthapani
Journal:  Biometrics       Date:  2019-10-03       Impact factor: 2.571

6.  UCP2 regulates cholangiocarcinoma cell plasticity via mitochondria-to-AMPK signals.

Authors:  Jianhua Yu; Lawrence Shi; Xinggui Shen; Yunfeng Zhao
Journal:  Biochem Pharmacol       Date:  2019-05-11       Impact factor: 5.858

7.  Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.

Authors:  Adam R Wolfe; Bisrat G Debeb; Lara Lacerda; Richard Larson; Arvind Bambhroliya; Xuelin Huang; Francois Bertucci; Pascal Finetti; Daniel Birnbaum; Steven Van Laere; Parmeswaran Diagaradjan; Brian Ruffell; Nicholaus J Trenton; Khoi Chu; Walter Hittelman; Michael Diehl; Ilya Levental; Naoto T Ueno; Wendy A Woodward
Journal:  Breast Cancer Res Treat       Date:  2015-11-21       Impact factor: 4.872

Review 8.  Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy.

Authors:  Francesco Piva; Matteo Giulietti; Matteo Santoni; Giulia Occhipinti; Marina Scarpelli; Antonio Lopez-Beltran; Liang Cheng; Giovanni Principato; Rodolfo Montironi
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

9.  Overexpression of forkhead Box C2 promotes tumor metastasis and indicates poor prognosis in colon cancer via regulating epithelial-mesenchymal transition.

Authors:  Qingguo Li; Jitao Wu; Ping Wei; Ye Xu; Changhua Zhuo; Yuwei Wang; Dawei Li; Sanjun Cai
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

10.  Fusion of the Paired Box 3 (PAX3) and Myocardin (MYOCD) Genes in Pediatric Rhabdomyosarcoma.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Kristin Andersen; Marius Lund-Iversen; Svetlana Tafjord; Francesca Micci; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2021 Nov-Dec       Impact factor: 4.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.